OXFORD NANOPORE TECHNOLOGIES PLC Financials Oxford Nanopore Technologies plc
Equities
ONT
GB00BP6S8Z30
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 98.35 GBX | -5.61% |
|
-4.05% | -52.76% |
| Apr. 22 | Jefferies raises B&M to 'hold' | AN |
| Apr. 02 | EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises | AN |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 5,726 | 2,034 | 896.1 | 896.1 | - |
| Enterprise Value (EV) 1 | 5,263 | 1,712 | 1,560 | 583.2 | 700.8 |
| P/E ratio | -30.3 x | -22.4 x | -11 x | -6.18 x | -7.05 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 42.8 x | 10.2 x | 10.5 x | 4.74 x | 3.69 x |
| EV / Revenue | 39.4 x | 8.62 x | 9.19 x | 3.08 x | 2.88 x |
| EV / EBITDA | -91.2 x | -21.8 x | -14.9 x | -5.72 x | -9.25 x |
| EV / FCF | -69.8 x | -18.7 x | -3.64 x | -4.55 x | -6.39 x |
| FCF Yield | -1.43% | -5.35% | -27.5% | -22% | -15.6% |
| Price to Book | 8.15 x | 2.93 x | 2.7 x | 1.76 x | 2.37 x |
| Nbr of stocks (in thousands) | 820,404 | 825,255 | 859,959 | 859,959 | - |
| Reference price 2 | 6.980 | 2.465 | 1.042 | 1.042 | 1.042 |
| Announcement Date | 3/22/22 | 3/21/23 | 3/6/24 | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 133.7 | 198.6 | 169.7 | 189.1 | 242.9 |
| EBITDA 1 | - | -57.7 | -78.63 | -104.9 | -101.9 | -75.77 |
| EBIT 1 | - | -82.9 | -110.5 | -146.6 | -147.7 | -126.3 |
| Operating Margin | - | -62.02% | -55.64% | -86.38% | -78.11% | -51.97% |
| Earnings before Tax (EBT) 1 | - | -166 | -83.41 | -149.8 | -145.9 | -117.7 |
| Net income 1 | -61.24 | -167.6 | -91.02 | -154.5 | -148.9 | -133.6 |
| Net margin | - | -125.4% | -45.83% | -91.06% | -78.76% | -55% |
| EPS 2 | -1.990 | -0.2300 | -0.1100 | -0.1900 | -0.1687 | -0.1479 |
| Free Cash Flow 1 | - | -75.36 | -91.62 | -128.4 | -128.1 | -109.7 |
| FCF margin | - | -56.38% | -46.13% | -75.9% | -67.74% | -45.14% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 8/2/21 | 3/22/22 | 3/21/23 | 3/6/24 | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales | 74.71 | 122.3 | 76.26 | 86 | 83.67 | 90 | 104 | 114 | 132 |
| EBITDA 1 | -25.86 | -34.61 | -44.02 | -39.37 | -65.56 | -28 | -26 | -19 | -17 |
| EBIT 1 | -39.33 | -22.96 | -59.76 | -74.78 | -87.32 | -52 | -46 | -48 | -41 |
| Operating Margin | -52.64% | -18.77% | -78.37% | -86.96% | -104.37% | -57.78% | -44.23% | -42.11% | -31.06% |
| Earnings before Tax (EBT) 1 | -121.6 | -27.63 | -55.78 | -66.56 | -83.21 | -51 | -46 | -48 | -41 |
| Net income 1 | -122.8 | -30.18 | -60.85 | -70.1 | -13.11 | -54 | -49 | -51 | -44 |
| Net margin | -164.35% | -24.66% | -79.8% | -81.51% | -15.67% | -60% | -47.12% | -44.74% | -33.33% |
| EPS 2 | -0.1100 | -0.0400 | -0.0700 | -0.0800 | -0.1100 | -0.0600 | -0.0600 | -0.0600 | -0.0500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/22/22 | 9/13/22 | 3/21/23 | 9/6/23 | 3/6/24 | - | - | - | - |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 463 | 323 | 228 | 313 | 195 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -75.4 | -91.6 | -128 | -128 | -110 |
| ROE (net income / shareholders' equity) | - | -19% | -13% | -23.1% | -24.8% | -31% |
| ROA (Net income/ Total Assets) | - | -15.1% | -10.9% | -19.3% | -24.1% | -29.7% |
| Assets 1 | - | 1,111 | 832.9 | 800.5 | 616.9 | 449.2 |
| Book Value Per Share 2 | - | 0.8600 | 0.8400 | 0.7700 | 0.5900 | 0.4400 |
| Cash Flow per Share 2 | - | -0.0700 | -0.0600 | -0.1600 | -0.1400 | -0.0800 |
| Capex 1 | - | 21.5 | 42.2 | 39.1 | 37.9 | 38.5 |
| Capex / Sales | - | 16.11% | 21.27% | 23.09% | 20.07% | 15.83% |
| Announcement Date | 8/2/21 | 3/22/22 | 3/21/23 | 3/6/24 | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
1.042
GBP
Average target price
2.02
GBP
Spread / Average Target
+93.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -52.76% | 1.12B | |
| +7.72% | 220B | |
| +6.38% | 183B | |
| +10.72% | 133B | |
| +24.24% | 107B | |
| -0.95% | 63.05B | |
| +11.23% | 51.74B | |
| +4.81% | 50.47B | |
| -1.05% | 40.91B | |
| +24.11% | 31.91B |
- Stock Market
- Equities
- ONT Stock
- Financials Oxford Nanopore Technologies plc
